Author

Gerhard C Hildebrandt

University of Missouri - Cited by 4,314 - hematology

Biography

Dr. Gerhard C Hildebrandt is a researcher and a scientist at Division of Hematology & Hematologic Malignancies, Huntsman Cancer Institute, University of Utah School of Medicine and has specialization in Orthopaedics, Osteosarcoma, Bone marrow transplant, Chondrosarcoma, Osteomyelitis, Bone Fracture, Bone marrow, Fibroblast, Osteogenic differentiation. 
Title
Cited by
Year
Outcomes associated with thiotepa-based conditioning in patients with primary central nervous system lymphoma after autologous hematopoietic cell transplant
M Scordo, TP Wang, KW Ahn, Y Chen, S Ahmed, FT Awan, A Beitinjaneh, ...JAMA oncology 7 (7), 993-1003, 2021202
39
2021
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation …
A Sehgal, D Hoda, PA Riedell, N Ghosh, M Hamadani, GC Hildebrandt, ...The Lancet Oncology 23 (8), 1066-1077, 2022202
30
2022
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
MJ Wieduwilt, L Metheny III, MJ Zhang, HL Wang, N Estrada-Merly, ...Blood advances 6 (1), 339-357, 2022202
30
2022
Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia
JR Rivas, Y Liu, SS Alhakeem, JM Eckenrode, F Marti, JP Collard, ...Leukemia 35 (11), 3188-3200, 2021202
23
2021
Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs …
GSG Murthy, S Kim, ZH Hu, N Estrada-Merly, MB Abid, M Aljurf, U Bacher, ...JAMA oncology 8 (3), 404-411, 202
22
2022
Allogeneic transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults
L Metheny, NS Callander, AC Hall, MJ Zhang, K Bo-Subait, HL Wang, ...Transplantation and cellular therapy 27 (11), 923. e1-923. e, 2021202
12
2021
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow …
M Mei, R Pillai, S Kim, N Estrada-Merly, M Afkhami, L Yang, Z Meng, ...Haematologica 8 (1), 150, 2023202
10
2023
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis
AM Jimenez Jimenez, M De Lima, KV Komanduri, TP Wang, MJ Zhang, ...Bone marrow transplantation 56 (12), 3068-3077, 2021202
10
2021
The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae
PG Richardson, M Palomo, NA Kernan, GC Hildebrandt, N Chao, ...Bone Marrow Transplantation 56 (12), 29-296, 2021202
8
2021
Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes
B Oran, KW Ahn, C Fretham, A Beitinjaneh, A Bashey, A Pawarode, ...Transplantation and cellular therapy 27 (11), 921. e1-921. e10, 2021202
8
2021
Chronic graft-versus-host disease, nonrelapse mortality, and disease relapse in older versus younger adults undergoing matched allogeneic peripheral blood hematopoietic cell …
VR Bhatt, T Wang, K Chen, CL Kitko, ML MacMillan, JA Pidala, ...Transplantation and cellular therapy 28 (1), 34-42, 2022202
6
2022
Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation …
A Sehgal, D Hoda, PA Riedell, N Ghosh, M Hamadani, G Hildebrandt, ...Journal of Clinical Oncology 40 (16_suppl), 7062-7062, 2022202
5
2022
Noninfectious pulmonary toxicity after allogeneic hematopoietic cell transplantation
SS Patel, KW Ahn, M Khanal, C Bupp, M Allbee-Johnson, NS Majhail, ...Transplantation and cellular therapy 28 (6), 310-320, 2022202
5
2022
Lisocabtagene Maraleucel for the treatment of B-cell lymphoma
C Iragavarapu, G HildebrandtExpert Opinion on Biological Therapy 21 (9), 111-116, 2021202
5
2021
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
K Menghrajani, A Gomez-Arteaga, R Madero-Marroquin, MJ Zhang, ...Blood advances 6 (3), 828-847, 2022202
5
2022
Correction to: An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR …
AM Jimenez Jimenez, M De Lima, KV Komanduri, TP Wang, MJ Zhang, ...Bone marrow transplantation 57 (5), 852-852, 2022202
4
2022
Randomized phase ii study to assess the role of nivolumab as single agent to eliminate minimal residual disease and maintain remission in acute myelogenous leukemia (AML …
H Liu, E Sharon, TG Karrison, Y Zha, N Fulton, H Streicher, K Sweet, ...Blood 10 (Supplement 1), 1716-1719, 2022202
4
2022
Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients
Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 11 AML patientsM Boyiadzis, MJ Zhang, K Chen, H Abdel-Azim, MB Abid, M Aljurf, ...Leukemia, 1-12, 2022202
3
2022
Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
GSG Murthy, S Kim, N Estrada-Merly, MB Abid, M Aljurf, A Assal, T Badar, ...Haematologica, 20220
3
2023
Adapting the HCT-CI definitions for children, adolescents, and young adults with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation
BD Friend, L Broglie, BR Logan, S Chhabra, C Bupp, G Schiller, ...Transplantation and cellular therapy 29 (2), 12. e1-12. e10, 20220
3
2023

Referred From: https://scholar.google.com/citations?user=geCZvI4AAAAJ&hl=en

Cited by
Citations 4314
h-index 34
i10-index 99
Recommended Journals
Open Access Journals